NCI strategy for evaluating MCED assays may bypass cancer clinical trials groups June 24, 2022Vol.48 No.25By Paul Goldberg and Alice Tracey
FreeIn the Archives Survivor Stories: Rob Krigel, Nedra Bonds, Stacey Smith June 24, 2022Vol.48 No.25
Trials & Tribulations Transforming the future of radiation oncology:Three ways collaboration accelerates FLASH radiation therapy research June 24, 2022Vol.48 No.25By Karen J. Kirkby
Conversation with The Cancer Letter Julie Bauman: Washington, DC, needs one more NCI-designated cancer center—and it matters that a woman runs it June 17, 2022Vol.48 No.24By Paul Goldberg
NCI Doug Lowy: NCI to fund MCED research, early-stage investigator diversity in Moonshot 2.0 June 17, 2022Vol.48 No.24By Alice Tracey
FreeObituary Neuroblastoma researcher Robert C. Seeger dies at 82 June 17, 2022Vol.48 No.24By Katherine K. Matthay, Judith G. Villablanca, C. Patrick Reynolds and John M. Maris
FreeIn the Archives Dave Boule confronted polycythemia vera with an accountant’s consistency June 17, 2022Vol.48 No.24
Trials & Tribulations ANCHOR trial shows that treatment of anal high-grade squamous intraepithelial lesions prevents anal cancer in people with HIV June 17, 2022Vol.48 No.24By Joel M. Palefsky and Robert Yarchoan
